Tandem-multimeric F3-gelonin fusion toxins for enhanced anti-cancer activity for prostate cancer treatment.

[1]  Kit S Lam,et al.  Corrigendum to 'Tumor-targeting peptides from combinatorial libraries' [Adv Drug Deliv Rev.110-111 (2017) 13-37]. , 2018, Advanced drug delivery reviews.

[2]  Kit S Lam,et al.  Tumor-targeting peptides from combinatorial libraries. , 2017, Advanced drug delivery reviews.

[3]  Han-Chung Wu,et al.  Peptide-conjugated nanoparticles for targeted imaging and therapy of prostate cancer. , 2016, Biomaterials.

[4]  S. Khan,et al.  PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer. , 2016, Colloids and surfaces. B, Biointerfaces.

[5]  A. Di Maro,et al.  A new age for biomedical applications of Ribosome Inactivating Proteins (RIPs): from bioconjugate to nanoconstructs , 2016, Journal of Biomedical Science.

[6]  K. Min,et al.  Preparation and Characterization of Gelonin-Melittin Fusion Biotoxin for Synergistically Enhanced Anti-Tumor Activity , 2016, Pharmaceutical Research.

[7]  N. Xing,et al.  Combination of Quercetin and 2-Methoxyestradiol Enhances Inhibition of Human Prostate Cancer LNCaP and PC-3 Cells Xenograft Tumor Growth , 2015, PloS one.

[8]  Xin-guo Jiang,et al.  Tumor homing cell penetrating peptide decorated nanoparticles used for enhancing tumor targeting delivery and therapy. , 2015, International journal of pharmaceutics.

[9]  M. Melzig,et al.  Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy , 2014, Current pharmaceutical design.

[10]  Zhirong Zhang,et al.  Increased tumor targeted delivery using a multistage liposome system functionalized with RGD, TAT and cleavable PEG. , 2014, International journal of pharmaceutics.

[11]  W. Trommer,et al.  Chemically and biologically synthesized CPP-modified gelonin for enhanced anti-tumor activity. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[12]  Chen Jiang,et al.  T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting. , 2013, International journal of pharmaceutics.

[13]  Yun Hee Cho,et al.  Fusion Toxin BLyS-Gelonin Inhibits Growth of Malignant Human B Cell Lines In Vitro and In Vivo , 2012, PloS one.

[14]  Yongzhuo Huang,et al.  TAT-modified nanosilver for combating multidrug-resistant cancer. , 2012, Biomaterials.

[15]  L. O’Driscoll,et al.  Characterisation and manipulation of docetaxel resistant prostate cancer cell lines , 2011, Molecular Cancer.

[16]  A. Hovanessian,et al.  Surface Expressed Nucleolin Is Constantly Induced in Tumor Cells to Mediate Calcium-Dependent Ligand Internalization , 2010, PloS one.

[17]  M. Ozkan,et al.  A surface-charge study on cellular-uptake behavior of F3-peptide-conjugated iron oxide nanoparticles. , 2009, Small.

[18]  J. Briand,et al.  The cell surface expressed nucleolin is a glycoprotein that triggers calcium entry into mammalian cells. , 2009, Experimental cell research.

[19]  André Pèlegrin,et al.  Cell-penetrating and cell-targeting peptides in drug delivery. , 2008, Biochimica et biophysica acta.

[20]  Ralph Weissleder,et al.  Multifunctional magnetic nanoparticles for targeted imaging and therapy. , 2008, Advanced drug delivery reviews.

[21]  Yanfeng Qu,et al.  Truncations of gelonin lead to a reduction in its cytotoxicity. , 2007, Toxicology.

[22]  Raoul Kopelman,et al.  Vascular Targeted Nanoparticles for Imaging and Treatment of Brain Tumors , 2006, Clinical Cancer Research.

[23]  Erkki Ruoslahti,et al.  Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels , 2003, The Journal of cell biology.

[24]  Johannes Waltenberger,et al.  In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Erkki Ruoslahti,et al.  A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Behr,et al.  Conjugation of Folate via Gelonin Carbohydrate Residues Retains Ribosomal-inactivating Properties of the Toxin and Permits Targeting to Folate Receptor Positive Cells* , 2001, The Journal of Biological Chemistry.

[27]  M. Khazaeli,et al.  Use of chlorotoxin for targeting of primary brain tumors. , 1998, Cancer research.

[28]  R Langer,et al.  Characterization and development of RGD-peptide-modified poly(lactic acid-co-lysine) as an interactive, resorbable biomaterial. , 1997, Journal of biomedical materials research.

[29]  A. Surolia,et al.  X-ray structure of gelonin at 1.8 A resolution. , 1995, Journal of molecular biology.

[30]  F. Stirpe,et al.  Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. Isolation, characterization, and preparation of cytotoxic complexes with concanavalin A. , 1980, The Journal of biological chemistry.

[31]  K. Min,et al.  Recombinant TAT-gelonin fusion toxin: synthesis and characterization of heparin/protamine-regulated cell transduction. , 2015, Journal of biomedical materials research. Part A.

[32]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[33]  Quanyin Hu,et al.  F3 peptide-functionalized PEG-PLA nanoparticles co-administrated with tLyp-1 peptide for anti-glioma drug delivery. , 2013, Biomaterials.

[34]  Kit S Lam,et al.  Therapeutic cancer targeting peptides. , 2002, Biopolymers.

[35]  M. Rosenblum,et al.  Cited Articles Citing Articles E-mail Alerts Design, Expression, Purification, and Characterization, in Vitro and in Vivo, of an Antimelanoma Single-chain Fv Antibody Fused to the Toxin Gelonin , 2022 .